BioNTech SE (BNTX) Return on Equity (ROE): -6.79%
Is BioNTech SE’s return on equity (ROE) high or low?
BioNTech SE's return on equity (ROE) of -6.79% is 131% below its 5-year average of 21.70%, near the low end of its 5-year range (-5.68%–86.54%).
The return on equity (ROE) for BioNTech SE (BNTX) is -6.79% as of Wednesday, June 10, 2026. It is below its 12-month average by 49.07% (-4.55%).
BNTX Return on Equity (ROE) Chart
BNTX Average Return on Equity (ROE) Chart
BNTX Current vs Average Return on Equity (ROE) Chart
BNTX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-6.79%
RETURN ON EQUITY (ROE) AVG TTM
-4.55%
RETURN ON EQUITY (ROE) AVG 3Y
10.63%
RETURN ON EQUITY (ROE) AVG 5Y
21.70%
RETURN ON EQUITY (ROE) AVG 10Y
24.96%
RETURN ON EQUITY (ROE) AVG 15Y
24.96%
RETURN ON EQUITY (ROE) AVG 20Y
24.96%
CURRENT VS TTM AVG
-49.07%
CURRENT VS 3Y AVG
-163.86%
CURRENT VS 5Y AVG
-131.30%
CURRENT VS 10Y AVG
-127.20%
CURRENT VS 15Y AVG
-127.20%
CURRENT VS 20Y AVG
-127.20%
BNTX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | -6.79% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
| Moderna, Inc. (MRNA) | $18.40B | -43.12% | -32.64% | -13.90% | 0.25% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Veeva Systems Inc. (VEEV) | $27.37B | 12.60% | 12.42% | 12.32% | 13.45% |
| Biogen Inc. (BIIB) | $29.00B | 7.36% | 8.42% | 11.86% | 16.52% |
| DexCom, Inc. (DXCM) | $29.24B | 31.47% | 28.93% | 25.01% | 22.95% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.26% | 21.77% | 21.17% | 17.55% |
| Align Technology, Inc. (ALGN) | $12.56B | 10.36% | 10.54% | 10.84% | 19.93% |
Return Analysis
ROE
-6.8%
ROA
-6.0%
BioNTech SE Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for BioNTech SE (BNTX)?
- The return on equity (ROE) for BNTX stock is -6.79%.
- Is BioNTech SE's return on equity (ROE) high or low?
- BioNTech SE's return on equity (ROE) of -6.79% is 131% below its 5-year average of 21.70%, near the low end of its 5-year range (-5.68%–86.54%).
- What is the TTM average return on equity (ROE) for BioNTech SE (BNTX)?
- The TTM average return on equity (ROE) for BNTX stock is -4.55%.
- What is the 3Y average return on equity (ROE) for BioNTech SE (BNTX)?
- The 3Y average return on equity (ROE) for BNTX stock is 10.63%.
- What is the 5Y average return on equity (ROE) for BioNTech SE (BNTX)?
- The 5Y average return on equity (ROE) for BNTX stock is 21.70%.
- What is the 10Y average return on equity (ROE) for BioNTech SE (BNTX)?
- The 10Y average return on equity (ROE) for BNTX stock is 24.96%.
- What is the 15Y average return on equity (ROE) for BioNTech SE (BNTX)?
- The 15Y average return on equity (ROE) for BNTX stock is 24.96%.
- What is the 20Y average return on equity (ROE) for BioNTech SE (BNTX)?
- The 20Y average return on equity (ROE) for BNTX stock is 24.96%.
BioNTech SE Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -5.68% |
| 2024-12-31 | -3.43% |
| 2023-12-31 | 4.60% |
| 2022-12-31 | 47.04% |
| 2021-12-31 | 86.54% |
| 2020-12-31 | 1.11% |
| 2019-12-31 | -36.29% |
| 2018-12-31 | -18.04% |
| 2017-12-31 | 173.75% |
| 2016-12-31 | 0.00% |
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin